NYSE: MRK
Merck & Co Inc Stock

MRK Price
$75.89
Fair Value Price
N/A
Market Cap
$191.55B
52 Week Low
$66.40
52 Week High
$92.04
P/E
18.38x
P/B
6.93x
P/S
4.14x
PEG
1.06x
Dividend Yield
3.14%%
Revenue
$47.19B
Earnings
$10.48B
Gross Profit Margin
70.1%%
Operating Margin
26.43%%
Net Profit Margin
22.2%%
Debt to Equity
2.27
Operating Cash Flow
$13B
Beta
0.71
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

Zen Score

High
Medium
Low
57
Industry average

Reasons for this score

MRK ($75.89) is trading below its intrinsic value of $298.32, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
MRK is good value based on its earnings relative to its share price (18.38x), compared to the US market average 46.84x)
Valuation
MRK is good value based on its earnings relative to its share price (18.38x), compared to the US Drug Manufacturers - General industry average (-11.04x)
Valuation

1 of 13

MRK News

Valuation

MRK price to earnings (PE)

For valuing profitable companies with steady earnings
Company
18.38x
Industry
-11.04x
Market
46.84x
MRK is good value based on its earnings relative to its share price (18.38x), compared to the US market average 46.84x)
Valuation
MRK is good value based on its earnings relative to its share price (18.38x), compared to the US Drug Manufacturers - General industry average (-11.04x)
Valuation

MRK price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
6.93x
Industry
7.13x
Market
63.22x
MRK is good value based on its book value relative to its share price (6.93x), compared to the US market average (63.22x)
Valuation
MRK is good value based on its book value relative to its share price (6.93x), compared to the US Drug Manufacturers - General industry average (7.13x)
Valuation

MRK price to earnings growth (PEG)

For valuing profitable companies with growth potential
MRK is poor value relative to its rate of earnings growth, measured by PEG ratio (1.06x)
Valuation

MRK's financial health

Profit margin

Revenue
$12.1B
Net Income
$3.2B
Profit Margin
26.7%%
MRK's Earnings (EBIT) of $12.47B can safely cover interest payments on company debt ($30.87B)
Financials
MRK's profit margin has increased (+1.1%%) in the last year from (21.1%%) to (22.2%%)
Financials

Assets to liabilities

Assets
$84.9B
Liabilities
$58.6B
Debt to equity
1.07
MRK's short-term assets ($29.34B) exceed its short-term liabilities ($22.18B)
Financials
MRK's long-term liabilities ($40.69B) exceed its short-term assets ($29.34B)
Financials
MRK's debt has increased relative to shareholder equity (2.27), over the past 5 years ago (1.2)
Financials
MRK's debt to equity ratio (2.27) is considered high
Financials

Cash flow

Operating
$707.0M
Investing
-$1.6B
Financing
-$1.5B
MRK's operating cash flow ($13.09B) is sufficient to service the company's debt ($30.87B)
Financials

Merck & Stock FAQ

(NYSE: MRK) Merck & trades on the NYSE under the ticker symbol MRK. Merck & stock quotes can also be displayed as NYSE: MRK.
(NYSE: MRK) Merck & stock price per share is $75.89 today (as of Oct 29, 2020).
(NYSE: MRK) Merck &'s 52-week high was $92.04, and its 52-week low was $66.40. It is currently -17.55%% from its 52-week high and 14.29%% from its 52-week low.
(NYSE: MRK) Merck &'s market cap is $191.55B, as of Oct 30, 2020.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Merck &'s market cap is calculated by multiplying MRK's current stock price of $75.89 by MRK's total outstanding shares of 2,524,101,191.
(NYSE: MRK) Merck & currently has 2,524,101,191 outstanding shares. With Merck & stock trading at $75.89 per share, the total value of Merck & stock (market capitalization) is $191.55B.

Merck & stock was originally listed at a price of $53.00 in Dec 31, 1997. If you had invested in Merck & stock at $53.00, your return over the last 22 years would have been 43.19%%, for an annualized return of 1.65%%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics